JP2020531524A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020531524A5 JP2020531524A5 JP2020511314A JP2020511314A JP2020531524A5 JP 2020531524 A5 JP2020531524 A5 JP 2020531524A5 JP 2020511314 A JP2020511314 A JP 2020511314A JP 2020511314 A JP2020511314 A JP 2020511314A JP 2020531524 A5 JP2020531524 A5 JP 2020531524A5
- Authority
- JP
- Japan
- Prior art keywords
- her2
- mva
- cancer
- cells
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17187824.2 | 2017-08-24 | ||
| EP17187824 | 2017-08-24 | ||
| PCT/EP2018/072789 WO2019038388A1 (en) | 2017-08-24 | 2018-08-23 | POLYTHERAPY FOR THE TREATMENT OF CANCER BY INTRAVENOUS ADMINISTRATION OF RECOMBINANT MVA AND ANTIBODY |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020531524A JP2020531524A (ja) | 2020-11-05 |
| JP2020531524A5 true JP2020531524A5 (https=) | 2022-09-07 |
| JP7202362B2 JP7202362B2 (ja) | 2023-01-11 |
Family
ID=59702586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511314A Active JP7202362B2 (ja) | 2017-08-24 | 2018-08-23 | 組み換えｍｖａ及び抗体の静脈内投与を用いた、がん治療のための併用療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11273211B2 (https=) |
| EP (1) | EP3691675A1 (https=) |
| JP (1) | JP7202362B2 (https=) |
| KR (1) | KR102754876B1 (https=) |
| CN (1) | CN111050790B (https=) |
| AU (1) | AU2018320417B2 (https=) |
| BR (1) | BR112020003669A2 (https=) |
| CA (1) | CA3073310A1 (https=) |
| IL (1) | IL272546B2 (https=) |
| MX (1) | MX2020001856A (https=) |
| SG (1) | SG11202001115TA (https=) |
| WO (1) | WO2019038388A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| CR20220220A (es) | 2019-11-18 | 2022-09-20 | Janssen Biotech Inc | Vacunas basadas en calr y jak2 mutantes y sus usos |
| US20230190922A1 (en) * | 2019-11-20 | 2023-06-22 | Bavarian Nordic A/S | Recombinant MVA Viruses for Intratumoral and/or Intravenous Administration for Treating Cancer |
| IL293012A (en) * | 2019-11-20 | 2022-07-01 | Bavarian Nordic As | Medicinal uses of 4-1bbl modified ankara virus vaccinia ((recombinant mva |
| US12194157B2 (en) | 2020-04-09 | 2025-01-14 | Finncure Oy | Carrier for targeted delivery to a host |
| FI20215508A1 (en) | 2020-04-09 | 2021-10-10 | Niemelae Erik Johan | Mimetic nanoparticles to prevent the spread of new coronaviruses and reduce the rate of infection |
| CA3183774A1 (en) * | 2020-06-26 | 2021-12-30 | National Breast Cancer Coalition | Breast cancer vaccine |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| WO2022192268A1 (en) * | 2021-03-10 | 2022-09-15 | University Of Iowa Research Foundation | Methods of enhancing antibody therapies |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766598A (en) | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products |
| AU731860B2 (en) | 1996-07-25 | 2001-04-05 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Recombinant pox virus for immunization against tumor-associated antigens |
| EP1865065A1 (en) * | 1998-12-09 | 2007-12-12 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | A recombinant vector expressing multiple costimulatory molecules and uses thereof |
| UA76731C2 (uk) | 2000-11-23 | 2006-09-15 | Баваріан Нордік А/С | Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації |
| DE60235041D1 (de) | 2001-11-30 | 2010-02-25 | Us Gov Health & Human Serv | Und ihre verwendung |
| EP2345665A3 (en) | 2001-12-04 | 2012-02-15 | Bavarian Nordic A/S | Flavivirus NS1 subunit vaccine |
| CN101173282B (zh) * | 2003-07-21 | 2011-04-06 | P.安杰莱蒂分子生物学研究所 | 编码人表皮生长因子2/neu抗原的合成基因及其用途 |
| NZ592082A (en) | 2008-11-27 | 2013-03-28 | Bavarian Nordic As | Promoters for recombinant viral expression |
| US8394385B2 (en) | 2009-03-13 | 2013-03-12 | Bavarian Nordic A/S | Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines |
| MX2011010977A (es) | 2009-04-17 | 2012-02-29 | Us Health | Composiciones inmunoterapeuticas combinadas contra cancer y metodos. |
| WO2013189611A1 (en) | 2012-06-22 | 2013-12-27 | Bavarian Nordic A/S | Poxviral vectors for low antibody response after a first priming immunization |
| WO2014037124A1 (en) | 2012-09-04 | 2014-03-13 | Bavarian Nordic A/S | Methods and compositions for enhancing vaccine immune responses |
| WO2014043535A1 (en) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions for the treatment of cancer |
| WO2014043518A1 (en) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use |
| EP2908851A1 (en) | 2012-10-19 | 2015-08-26 | Bavarian Nordic Inc. | Methods and compositions for the treatment of cancer |
| EP2912183B1 (en) | 2012-10-28 | 2020-05-06 | Bavarian Nordic A/S | Pr13.5 promoter for robust t-cell and antibody responses |
| US9725494B2 (en) * | 2013-05-17 | 2017-08-08 | United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Soluble CD27 (sCD27) and the use thereof |
| AU2014347004B2 (en) | 2013-11-05 | 2019-08-08 | Bavarian Nordic A/S | Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and an antagonist and/or agonist of an immune checkpoint inhibitor |
| UA127337C2 (uk) * | 2013-11-28 | 2023-07-26 | Баваріан Нордік А/С | Рекомбінантний поксвірус для індукції посиленої імунної відповіді та його застосування |
| KR102499737B1 (ko) * | 2014-05-13 | 2023-02-13 | 버베리안 노딕 에이/에스 | 종양 항원을 발현하는 재조합 폭스바이러스 및 면역 체크포인트 분자 길항제 또는 효현제로 암을 치료하기 위한 복합 요법 |
| EP3166646A4 (en) | 2014-07-07 | 2018-03-07 | Duke University | Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same |
| JP2017530114A (ja) * | 2014-09-26 | 2017-10-12 | バヴァリアン・ノルディック・アクティーゼルスカブ | フラジェリンをコードする組み換えｍｖａによる鼻腔内免疫のための方法と組成物 |
| ES2901468T3 (es) | 2015-07-31 | 2022-03-22 | Bavarian Nordic As | Promotores para mejorar la expresión en poxvirus |
| CA3119503A1 (en) * | 2018-11-20 | 2020-05-28 | Bavarian Nordic A/S | Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l |
| IL293012A (en) * | 2019-11-20 | 2022-07-01 | Bavarian Nordic As | Medicinal uses of 4-1bbl modified ankara virus vaccinia ((recombinant mva |
| WO2023118508A1 (en) * | 2021-12-23 | 2023-06-29 | Bavarian Nordic A/S | Recombinant mva viruses for intraperitoneal administration for treating cancer |
-
2018
- 2018-08-23 CN CN201880054776.8A patent/CN111050790B/zh active Active
- 2018-08-23 WO PCT/EP2018/072789 patent/WO2019038388A1/en not_active Ceased
- 2018-08-23 IL IL272546A patent/IL272546B2/en unknown
- 2018-08-23 BR BR112020003669-2A patent/BR112020003669A2/pt unknown
- 2018-08-23 CA CA3073310A patent/CA3073310A1/en active Pending
- 2018-08-23 EP EP18756447.1A patent/EP3691675A1/en active Pending
- 2018-08-23 SG SG11202001115TA patent/SG11202001115TA/en unknown
- 2018-08-23 AU AU2018320417A patent/AU2018320417B2/en active Active
- 2018-08-23 JP JP2020511314A patent/JP7202362B2/ja active Active
- 2018-08-23 KR KR1020207005076A patent/KR102754876B1/ko active Active
- 2018-08-23 MX MX2020001856A patent/MX2020001856A/es unknown
- 2018-08-23 US US16/641,236 patent/US11273211B2/en active Active
-
2022
- 2022-03-14 US US17/693,716 patent/US11723964B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11723964B2 (en) | Combination therapy for treating cancer with an antibody and intravenous administration of a recombinant MVA | |
| JP2020531524A5 (https=) | ||
| AU2019385665B2 (en) | Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-ibbl (cd137l) and/or cd40l | |
| JP7555334B2 (ja) | 組み換えｍｖａ、及び免疫チェックポイントアンタゴニストまたは免疫チェックポイントアゴニストの静脈内投与によって、がんを治療する併用療法 | |
| EP4452305A1 (en) | Recombinant mva viruses for intraperitoneal administration for treating cancer | |
| US20230190922A1 (en) | Recombinant MVA Viruses for Intratumoral and/or Intravenous Administration for Treating Cancer | |
| US20250002606A1 (en) | Combination Therapy for Treating Cancer with an Antibody and Intravenous Administration of a Recombinant MVA | |
| RU2795103C2 (ru) | Комбинированная терапия для лечения рака путем внутривенного введения рекомбинантного mva и антитела | |
| CA3240596A1 (en) | Therapy for modulating immune response with recombinant mva encoding il-12 |